

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7435938

|   |  |                       |
|---|--|-----------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT   |                       |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT   |                       |
| <b>CONVEYING PARTY DATA</b>   |  |                       |
|   | <b>Name</b>  | <b>Execution Date</b> |
|   | CELL MEDICA INC.   | 06/09/2022            |
| <b>RECEIVING PARTY DATA</b>   |  |                       |
| <b>Name:</b>  | CELL MEDICA, INC.  |                       |
| <b>Street Address:</b>  | 2617 BISSONNET ST, SUITE 300   |                       |
| <b>City:</b>  | HOUSTON  |                       |
| <b>State/Country:</b>   | TEXAS  |                       |
| <b>Postal Code:</b>   | 77005  |                       |
| <b>PROPERTY NUMBERS Total: 3</b>  |  |                       |
| <b>Property Type</b>  | <b>Number</b>  |                       |
| <b>Application Number:</b>  | 61738223   |                       |
| <b>Application Number:</b>  | 16783339   |                       |
| <b>Application Number:</b>  | 61220503   |                       |
| <b>CORRESPONDENCE DATA</b>  |  |                       |
| <b>Fax Number:</b>  |  |                       |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |  |                       |
| <b>Email:</b>   | ipdocketing@arnoldporter.com, angela.cox@arnoldporter.com, bonnie.qin@arnoldporter.com |                       |
| <b>Correspondent Name:</b>  | ARNOLD & PORTER KAYE SCHOLER LLP   |                       |
| <b>Address Line 1:</b>  | 601 MASSACHUSETTS AVE., NW   |                       |
| <b>Address Line 4:</b>  | WASHINGTON, D.C. 20001-3743  |                       |
| <b>NAME OF SUBMITTER:</b>   | CHUNBO QIN   |                       |
| <b>SIGNATURE:</b>   | /Chunbo Qin/   |                       |
| <b>DATE SIGNED:</b>   | 07/18/2022   |                       |
| <b>Total Attachments: 5</b>   |  |                       |
| source=ConfirmatoryAssignment#page1.tif   |  |                       |
| source=ConfirmatoryAssignment#page2.tif   |  |                       |
| source=ConfirmatoryAssignment#page3.tif   |  |                       |
| source=ConfirmatoryAssignment#page4.tif   |  |                       |
| source=ConfirmatoryAssignment#page5.tif   |  |                       |

## CONFIRMATORY ASSIGNMENT

WHEREAS, a Patent Agreement Assignment ("prior assignment") was executed by assignor Cell Medica Switzerland AG, ("Assignor") which states that Cell Medica Inc., of 2617 Bissonnet St, Suite 300, Houston, Texas 77005, a corporation of the state of Texas, is desirous of acquiring the entire right, title and interest in and to said inventions listed on Appendix A attached hereto, and any and all patents to be obtained therefor;

WHEREAS, in said prior assignment in which transfer of said entire right, title and interest in and to said inventions listed on Appendix A attached hereto, and any and all patents to be obtained therefor was documented, through error, a comma was inadvertently omitted in Assignee's company name; and

WHEREAS, it is the intent of Cell Medica Switzerland AG, as well as Cell Medica, Inc., through this Confirmatory Assignment document, to confirm the prior assignment of said entire right, title and interest in and to said inventions listed on Appendix A attached hereto, and any and all patents to be obtained therefor to Cell Medica, Inc., of 2617 Bissonnet St, Suite 300, Houston, Texas 77005, a corporation of the state of Texas;

NOW, THEREFORE, FOR GOOD AND VALUABLE CONSIDERATION, the receipt of which is hereby acknowledged, we do hereby confirm that Cell Medica Switzerland AG, has sold, assigned, transferred and conveyed to Cell Medica, Inc. the entire right, title and interest in and to those patent rights listed on Appendix A attached hereto, including the right to claim priority from the same in the United States and all foreign countries, and to claim the priority from the same as provided by the Paris Convention, together in each case with all registrations, applications therefor, patents (as applicable) issuing from any applications therefor, and renewals and extensions of the foregoing in the United States and for all foreign countries that are or may be secured under the laws of the United States and all foreign countries, including any division, renewal, continuation in whole or in part, substitution, conversion, reissue, reexamination, prolongation or extension thereof, now or hereafter in effect, for Assignee's own use and enjoyment as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment and sale had not been made, together with all income, royalties or payments due or payable as of the Effective Date or thereafter, including all claims for damages by reason of past, present or future infringement, misappropriation or other unauthorized use of such patents with the right to sue for and collect the same for Assignee's own use and enjoyment (collectively, the "**Assigned Patent Rights**"). Assignor hereby waives and agrees not to enforce any rights of attribution and integrity and other moral rights Assignor may have in the Assigned Patent Rights.

We hereby confirm that we authorize and request the issuing authority to issue any and all patents on said application or applications to Cell Medica, Inc., as assignee of the entire interest.

We further confirm that we agreed, without any payment by Cell Medica, Inc., other than in reimbursement of reasonable expenses we may incur, to communicate to Cell Medica, Inc., its representatives or agents, any facts relating to said inventions listed on Appendix A attached hereto or improvements, including evidence for purposes of interference, opposition or other legal proceedings, whenever requested; testify in any interference, opposition or other legal proceedings, whenever requested; and execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective.

*[signature page follows]*

The undersigned, whose title is supplied below, is authorized to act on behalf of said Assignor.

**ACCEPTED BY ASSIGNOR:**

Cell Medica Switzerland AG

By:

  
Martin Niederberger

Name

Title

LIQUIDATOR

Date:


02.06.2022

The undersigned, whose title is supplied below, is authorized to act on behalf of said Assignee.

**ACCEPTED BY ASSIGNEE:**

Cell Medica, Inc.

By:

  
Name Daniel Lang

Title President

Date:

June 24, 2022

[Signature Page to Patent Assignment]

**SCHEDULE A**

**ASSIGNED PATENT RIGHTS**

| Cell Medica<br>Ref. No. | Appln. No.<br>(Pub. No.)              | Patent No.   | Filing Date<br>(Pub. date)              | Issue Date    | Title   | Country                     |
|-------------------------|---------------------------------------|--------------|---|---------------|---|-----------------------------|
| P1602                   | PCT/EP2017/054367<br>(WO 2017/144681) |              | 24 February 2017<br>(31 August 2017)    |               | Binding Members to PD-L1  | PCT                         |
| P1602 USF               | US 16/079,210<br>(US 2019055312)      |              | 24 February 2017<br>(21 February 2019)  |               | Binding Members to PD-L1  | United States<br>of America |
| P1702 WOF               | PCT/US2017/019301<br>(WO 2017/147383) |              | 24 February 2017<br>(31 August 2017)    |               | Modified Cells for Immunotherapy  | PCT                         |
| P1702 USF               | US 16/079,202<br>(US 2019/0048085)    |              | 23 August 2018<br>(14 February 2019)    |               | Modified Cells for Immunotherapy  | United States<br>of America |
| P2295 USF               | US 14/740,434<br>(US 2016/194392)     | US 9,914,772 | 16 June 2015<br>(7 July 2016)           | 13 March 2018 | Antibodies Against IL-1 Beta  | United States<br>of America |
| P2295 USF1              | US 15/896,309<br>(US 2018/258165)     |              | 14 February 2018<br>(13 September 2018) |               | Antibodies Against IL-1 Beta  | United States<br>of America |
| P2295 WOF               | PCT/CH2008/000284<br>(WO 2009/000098) |              | 25 June 2008<br>(31 December 2008)      |               | Sequence Based Engineering and Optimization<br>of Single Chain Antibodies | PCT                         |
| P2323 WOF               | PCT/EP2013/076831<br>(WO 2014/095808) |              | 17 December 2013<br>(26 June 2014)      |               | Antibodies Against IL-1 Beta  | PCT                         |
| P2323                   | PCT/EP2013/073009<br>(WO 2014/068132) |              | 5 November 2013<br>(8 May 2014)         |               | Binding Members to IL-1 Beta  | PCT                         |
| P2323                   | US 14/072,165<br>(US 2014/0134183)    | US 9,404,930 | 5 November 2013<br>(15 May 2014)        | 2 August 2016 | Antibody to Human IL-1 Beta   | United States<br>of America |

| Cell Medica<br>Ref. No. | Appln. No.<br>(Pub. No.)              | Patent No.    | Filing Date<br>(Pub. date)           | Issue Date        | Title  | Country                     |
|-------------------------|---------------------------------------|---------------|--------------------------------------|-------------------|--|-----------------------------|
| P2323                   | USSN 15/202,982<br>(US 2017/0051054)  | US 10,077,302 | 6 July 2016<br>(23 February 2017)    | 18 September 2018 | Method of Inhibiting Human IL-1 Beta by<br>Administering an Antibody to Human IL-1<br>Beta | United States<br>of America |
| P2323                   | USSN 16/118,124<br>(US 2018/0362642)  | US 10,626,171 | 30 August 2018<br>(20 December 2018) | 21 April 2020     | Nucleic Acid Encoding Antibody to Human IL-<br>1 Beta                                      | United States<br>of America |
| P2323                   | USSN 16/822,952<br>(US 2020/0239565)  |               | 18 March 2020<br>(30 July 2020)      |                   | Antibody to Human IL-1 Beta  | United States<br>of America |
| P2751                   | PCT/EP2015/056646<br>(WO 2015/144852) |               | 26 March 2015<br>(1 October 2015)    |                   | Binding Members to TNF Alpha   | PCT                         |
| P2751                   | USSN 15/127,976<br>(US 2017/107282)   | US 10,233,238 | 26 March 2015<br>(20 April 2017)     | 19 March 2019     | TNF Alpha Antibody or Fragment Thereof and<br>Methods of Use                               | United States<br>of America |
| P2751                   | USSN 16/258,886<br>(US 2019/144532)   |               | 28 January 2019<br>(16 May 2019)     |                   | Binding Members to TNF Alpha   | United States<br>of America |
| P3786                   | USSN 12/823,488                       | US 8,399,624  | 25 June 2010                         | 19 March 2013     | Acceptor Framework for CDR Grafting  | United States<br>of America |
| P3786                   | USSN 13/765,326<br>(US 2013/0165640)  | US 9,051,366  | 12 February 2013<br>(27 June 2013)   | 9 June 2015       | Acceptor Framework for CDR Grafting  | United States<br>of America |
| P3786                   | USSN 14/706,484<br>(US 2015/0315294)  | US 9,403,903  | 7 May 2015<br>(5 November 2015)      | 2 August 2016     | Acceptor Framework for CDR Grafting  | United States<br>of America |
| P3786                   | USSN 15/193,432<br>(US 2016/0347864)  | US 9,994,645  | 27 June 2016<br>(1 December 2016)    | 12 June 2018      | Acceptor Framework for CDR Grafting  | United States<br>of America |
| P3786                   | USSN 16/005,138                       |               | 11 June 2018                         |                   | Acceptor Framework for CDR Grafting  | United States<br>of America |

| Cell Medica<br>Ref. No. | Appln. No.<br>(Pub. No.)              | Patent No.   | Filing Date<br>(Pub. date)           | Issue Date       | Title   | Country                     |
|-------------------------|---------------------------------------|--------------|--------------------------------------|------------------|---|-----------------------------|
| P3788                   | USSH 12/823,551                       | US 8,399,625 | 25 June 2010                         | 19 March 2013    | Acceptor Framework for CDR Grafting                   | United States<br>of America |
| P3788                   | USSH 13/765,302<br>(US 2013/0165639)  | US 9,005,924 | 12 February 2013<br>(27 June 2013)   | 14 April 2015    | Acceptor Framework for CDR Grafting                   | United States<br>of America |
| P3788                   | USSH 14/644,441<br>(US 2015/0232543)  | US 9,409,979 | 11 March 2015<br>(20 August 2015)    | 9 August 2016    | Acceptor Framework for CDR Grafting                   | United States<br>of America |
| P3788                   | USSH 15/195,411<br>(US 2016/0304627)  |              | 28 June 2016<br>(20 October 2016)    |                  | Acceptor Framework for CDR Grafting                   | United States<br>of America |
| P3788                   | USSH 16/879,978<br>(US 2020/0362059)  |              | 21 May 2020<br>(19 November 2020)    |                  | Acceptor Framework for CDR Grafting                   | United States<br>of America |
| P3791                   | PCT/CH2006/000300<br>(WO 2006/131013) |              | 6 June 2006<br>(14 December 2006)    |                  | Stable and Soluble Antibodies Inhibiting TNF $\alpha$ | PCT                         |
| P3791                   | USSH 11/916,793<br>(US 2009/0263382)  | US 8,067,547 | 6 June 2006<br>(22 October 2009)     | 29 November 2011 | Stable and Soluble Antibodies Inhibiting TNF $\alpha$ | United States<br>of America |
| P3791                   | USSH 13/245,420<br>(US 2012/0064077)  | US 8,389,693 | 26 September 2011<br>(15 March 2012) | 5 March 2013     | Stable and Soluble Antibodies Inhibiting TNF $\alpha$ | United States<br>of America |
| P3791                   | USSH 13/708,500<br>(US 2013/0171143)  | US 8,691,228 | 7 December 2012<br>(4 July 2013)     | 8 April 2014     | Stable and Soluble Antibodies Inhibiting TNF $\alpha$ | United States<br>of America |
| P3791                   | USSH 14/185,783<br>(US 2014/0171634)  | US 9,315,572 | 20 February 2014<br>(19 June 2014)   | 19 April 2016    | Stable and Soluble Antibodies Inhibiting TNF $\alpha$ | United States<br>of America |
| P3791                   | USSH 15/064,067<br>(US 2016/0185850)  | US 9,683,034 | 8 March 2016<br>(30 June 2016)       | 20 June 2017     | Stable and Soluble Antibodies Inhibiting TNF $\alpha$ | United States<br>of America |

PATENT

RECORDED: 07/18/2022

REEL: 060529 FRAME: 0588